Frontlight ResearchEarly access
CompletedNo phase
Evaluation of In-lab Benefit for Speech-in-noise Intelligibility With Device for Adults With Mild to Moderate Hearing Loss
Key facts
- Who runs it
- Luxottica Group S.p.A.
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 21 people enrolled
- Started
- 23 Jun 2025
- Ended
- 28 Aug 2025
- Type of study
- Interventional
- Treatments tested
- Evaluation of speech-in-noise intelligibility and listening effort
- Record updated
- 5 September 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Adults aged 18 years and older
- symmetrical bilateral mild to moderate sensorineural hearing loss
- native speakers of English
Who cannot take part
- Children
- those without hearing loss
- those without symmetrical bilateral mild to moderate sensorineural hearing loss
- those who do not wish to wear the test device instead of their own spectacles during the in-lab procedure
- those who are not native speakers of English
- those who have pacemakers, other implantable devices, or insulin pumps
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Evaluation of in-lab benefit for speech-in-noise intelligibility with the device for adults with mild to moderate hearing loss.
The group in the trial
- A prospective in-lab within-subjects design with repeated measuresTreatment being tested
Test of speech recognition in noise (the Matrix test). Assessment of speech recognition in babble (The Connected Speech Test). Device users' ratings of listening effort in noise with and without the device.
Treatment: Evaluation of speech-in-noise intelligibility and listening effort
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- In-Lab Evaluation of A Hearing Aid Housed in Ophthalmic Spectacles for Mild to Moderate Hearing Loss
- Record updated
- 5 September 2025